Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Alison Forgie"'
Autor:
Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in-human, multicenter, open-label, phase I, dose-escalation/dose-expansion study expl
Externí odkaz:
https://doaj.org/article/ccd14bbe12da44b9bec3de265e3da2d8
Autor:
James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
P-cadherin is a cell-cell adhesion molecule that is overexpressed in several solid tumors. PF-06671008 is a T-cell–redirecting bispecific antibody that engages both P-cadherin on tumors and CD3ϵ on T cells and induces antitumor activity in preclin
Externí odkaz:
https://doaj.org/article/cbbc152e331a4efbaff13402339432fe
Autor:
Bhumsuk Keam, Kevin Harrington, Ezra Cohen, Jean-Pascal Machiels, Feng Jin, Alison Forgie, Shanhong Guan, Jaume Pons, Beatriz Cirauqui, Sjoukje Oosting, Tim Welliver, Philip Fanning, Katherine Ruffner, Sophia Randolph
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d858740a794e4250bfede0ea7bc6d9c4
Autor:
Tae Min Kim, Yung-Jue Bang, Keun-Wook Lee, Patricia LoRusso, Wells Messersmith, Feng Jin, Nehal Lakhani, Alison Forgie, Justin Gainor, Jaume Pons, Hong Wan, Pierre Squifflet, Laura Chow, Philip Fanning, Sophia Randolph, Hyun Chung, Rafael Santana-Davila, Won Seog Kim
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/23de926803dc41fcbd797592f76630b0
Autor:
John C Lin, David Tsao, Paul Barras, Raul A Bastarrachea, Bob Boyd, Joyce Chou, Rodnie Rosete, Hua Long, Alison Forgie, Yasmina Abdiche, Jeanette Dilley, Jennifer Stratton, Carlos Garcia, David L Sloane, Anthony G Comuzzie, Arnon Rosenthal
Publikováno v:
PLoS ONE, Vol 3, Iss 4, p e1900 (2008)
Loss of function mutations in the receptor tyrosine kinase TrkB pathway resulted in hyperphagia and morbid obesity in human and rodents. Conversely, peripheral or central stimulation of TrkB by its natural ligands BDNF or NT4 reduced body weight and
Externí odkaz:
https://doaj.org/article/6efe3da8a10f430793c6095c8907968a
Autor:
Ezra Cohen, Kevin Harrington, Jean-Pascal Machiels, Sjoukje Oosting, Bhumsuk Keam, Beatriz Cirauqui, Annette Lim, Keun-Wook Lee, Tim Welliver, Christine Ju, Feng Jin, Alison Forgie, Jaume Pons, Sophia Randolph, Athanasios Tsiatis
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Kevin Harrington, Ezra Cohen, Bhumsuk Keam, Jean-Pascal Machiels, Sjoukje Oosting, Brett Hughes, Jong Chul Park, Tim Welliver, Christine Ju, Feng Jin, Alison Forgie, Jaume Pons, Sophia Randolph, Athanasios Tsiatis
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Alison Forgie, Melissa Lynne Johnson, Jeffrey Chou, Ira Jacobs, Xiao Wang, Siwen Hu-Lieskovan, Juneko E. Grilley-Olson, Fadi Braiteh, Vinicius Bonato
Publikováno v:
Targeted Oncology
Background Sasanlimab is a monoclonal antibody that binds to the programmed cell death receptor 1 (PD-1). Anti-PD-1 monoclonal antibodies have improved patient clinical outcomes; however, not all treated patients derive clinical benefit. Further insi
Autor:
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Jeffrey S Wasser, Eric Angevin, Patrick A Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B El-Khoueiry
Publikováno v:
Journal for ImmunoTherapy of Cancer, 10(10):e005471. BioMed Central Ltd.
BackgroundIvuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in-human, multicenter, open-label, phase I, dose-escalation/dose-expansion study explo
Autor:
James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong
Publikováno v:
Frontiers in immunology. 13
P-cadherin is a cell-cell adhesion molecule that is overexpressed in several solid tumors. PF-06671008 is a T-cell–redirecting bispecific antibody that engages both P-cadherin on tumors and CD3ϵ on T cells and induces antitumor activity in preclin